Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) demonstrated significant reductions in major adverse cardiovascular events, while others showed cardiovascular safety without superiority
JMIR Formative Research , 9, e72577.
Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer
Mixed reviews highlight the gap between promise and reality, making it a weak option for those seeking real GLP-1 treatment
The good news is that with the right approach, digestive discomfort can often be prevented or reduced